InfuSystem (INFU) 10-Q/A 12 Dec 16 2016 Q2 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 04, 2016
Document And Entity Information [Abstract]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	On November 1, 2016, the Audit Committee of the Board of Directors of InfuSystem Holdings, Inc. (the “Company”) concluded, after review and discussion with management, that the Company’s audited financial statements for the fiscal year ended December 31, 2015, and the Company’s unaudited financial statements for each of the fiscal quarters ended March 31, 2015 through June 30, 2016 (collectively, the “Financial Statements”) should no longer be relied upon. This Amendment No. 1 to the Company’s Quarterly Report on Form 10-Q (this “Form 10-Q/A”) for the three and six months ended June 30, 2016, which was filed with the U.S. Securities and Exchange Commission (“SEC”) on August 10, 2016 (the “Original Form 10-Q”), restates the Company’s consolidated financial statements as of and for the three and six months ended June 30, 2016, and amends the related Notes and disclosures thereto, including the Company’s controls and procedures.
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Trading Symbol	INFU
Entity Registrant Name	InfuSystem Holdings, Inc
Entity Central Index Key	1,337,013
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		22,633,972

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 805	$ 818
Accounts receivable, less allowance for doubtful accounts of $4,485 and $4,737 at June 30, 2016 and December 31, 2015, respectively	13,675	12,622
Inventory	2,096	1,916
Other current assets	1,207	861
Deferred income taxes	2,743	2,743
Total Current Assets	20,526	18,960
Medical equipment held for sale or rental	1,524	2,277
Medical equipment in rental service, net of accumulated depreciation	29,805	27,837
Property & equipment, net of accumulated depreciation	2,236	2,370
Intangible assets, net	31,855	31,534
Deferred income taxes	12,116	12,128
Other assets	222	251
Total Assets	98,284	95,357
Current Liabilities:
Accounts payable	5,346	6,586
Current portion of long-term debt	5,939	5,060
Other current liabilities	2,560	3,641
Total Current Liabilities	13,845	15,287
Long-term debt, net of current portion	33,482	29,750
Total Liabilities	47,327	45,037
Stockholders' Equity:
Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued
Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 22,821,647 and 22,623,987, respectively, as of June 30, 2016 and 22,739,550 and 22,541,890, respectively, as of December 31, 2015	2	2
Additional paid-in capital	91,681	91,238
Retained deficit	(40,726)	(40,920)
Total Stockholders' Equity	50,957	50,320
Total Liabilities and Stockholders' Equity	$ 98,284	$ 95,357

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 4,485	$ 4,737
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	22,821,647	22,739,550
Common stock, shares outstanding	22,623,987	22,541,890

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Net revenues:
Rentals	$ 16,242	$ 15,382	$ 32,730	$ 30,348
Product Sales	1,881	1,554	3,687	3,140
Net revenues	18,123	16,936	36,417	33,488
Cost of revenues:
Cost of revenues - Product, service and supply costs	4,789	3,656	8,295	6,671
Cost of revenues - Pump depreciation and disposals	2,191	1,660	4,422	3,281
Gross profit	11,143	11,620	23,700	23,536
Selling, general and administrative expenses:
Provision for doubtful accounts	1,067	1,143	2,814	2,337
Amortization of intangibles	922	713	1,834	1,344
Selling and marketing	2,324	2,687	5,139	5,424
General and administrative	6,392	5,994	13,061	11,969
Total selling, general and administrative	10,705	10,537	22,848	21,074
Operating income	438	1,083	852	2,462
Other income (expense):
Interest expense	(327)	(387)	(632)	(1,059)
Loss on extinguishment of long term debt				(1,599)
Other income	7		27	19
Total other expense	(320)	(387)	(605)	(2,639)
Income (loss) before income taxes	118	696	247	(177)
Income tax benefit (loss)	35	(54)	(53)	299
Net income	$ 153	$ 642	$ 194	$ 122
Net income per share:
Basic	$ 0.01	$ 0.03	$ 0.01	$ 0.01
Diluted	$ 0.01	$ 0.03	$ 0.01	$ 0.01
Weighted average shares outstanding:
Basic	22,620,386	22,381,487	22,584,462	22,345,309
Diluted	23,109,870	22,824,965	23,069,900	22,743,948

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Statement of Cash Flows [Abstract]
NET CASH PROVIDED BY OPERATING ACTIVITIES	$ 1,869	$ 3,787
INVESTING ACTIVITIES
Acquisition of business		(3,786)
Purchase of medical equipment and property	(7,187)	(9,474)
Proceeds from sale of medical equipment and property	1,827	1,876
NET CASH USED IN INVESTING ACTIVITIES	(5,360)	(11,384)
FINANCING ACTIVITIES
Principal payments on revolving credit facility, term loans and capital lease obligations	(29,190)	(43,586)
Cash proceeds from revolving credit facility	32,575	51,546
Debt issuance costs		(157)
Common stock repurchased to satisfy statutory withholding on employee stock based compensation plans	(33)	(48)
Cash proceeds from stock plans	126	118
NET CASH PROVIDED BY FINANCING ACTIVITIES	3,478	7,873
Net change in cash and cash equivalents	(13)	276
Cash and cash equivalents, beginning of period	818	515
Cash and cash equivalents, end of period	$ 805	$ 791

Basis of Presentation, Nature o

Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies	1. Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies The terms “InfuSystem”, “the Company”, “we”, “our” and “us” are used herein to refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services. The Company services hospitals, oncology practices and other alternative site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support, and also operates pump repair Centers of Excellence in Michigan, Kansas, California, Texas, Georgia and Ontario, Canada. The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying unaudited condensed consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and Notes thereto included in the Company’s Amendment No. 2 to its’ Annual Report on Form 10-K/A for the year ended December 31, 2015 as filed with the SEC. The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.

Restatement of Previously Issue

Restatement of Previously Issued Consolidated Financial Statements	6 Months Ended
	Jun. 30, 2016
Accounting Changes and Error Corrections [Abstract]
Restatement of Previously Issued Consolidated Financial Statements	2. Restatement of Previously Issued Consolidated Financial Statements Subsequent to the filing of the Company’s Quarterly Report on Form 10-Q for the three and six months ended June 30, 2016 with the SEC on August 10, 2016, management identified historical accounting errors principally related to a calculation error resulting in an overstatement of estimated accounts receivable collections. Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenues and accounts receivable at their net realizable value. Accounts receivable are reported at the estimated net realizable amounts from patients, third-party payors and other direct pay customers for goods provided and services rendered. The Company performs periodic analyses to assess the accounts receivable balances. The Company records an allowance for doubtful accounts and contractual allowance (to reduce gross billed charges to a contractual or estimated net realizable value from third-party payors) based on management’s assessment of historical and expected estimated collectability of the accounts such that the recorded amounts reflect estimated net realizable value. Upon determination that an account is uncollectible, the account is written-off and charged to the allowance for doubtful accounts for patients or the contractual allowance for third-party payors. The Company’s allowance for doubtful accounts and contractual allowance are a reduction to accounts receivable on the Company’s consolidated financial position. Additions to the contractual allowance each period offset gross billed charges, which are not publicly reported in the Company’s filings, to arrive at net revenue, which is publicly reported in the Company’s consolidated results of operations. Additions to the allowance for doubtful accounts, however, impact the bad debt expense line item of the Company’s consolidated results of operations. The Company discovered that it has been applying an incorrect cash collection percentage due to a calculation error when calculating the historical collection percentage from certain billings to third-parties. This calculation error resulted in an overstatement of historical cash collection percentages from this revenue, which was then used to estimate future cash collections relative to an outstanding accounts receivable balance. The calculation error affects only the Company’s rentals of infusion pumps to patients, which are paid for by third-party insurance payors. Revenue resulting from sales, service and rentals directly billed to health care providers is not impacted by this calculation error. The impact on the Company’s financial statements for the three and six months ended June 30, 2016 and 2015 is to increase the provision for contractual allowance (thereby reducing accounts receivable as shown on the balance sheet): Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) 2016 2015 2016 2015 Unaudited quarterly impact $ 943 $ 234 $ 1,693 $ 407 The impact of these amounts were included in the following items on the Company’s consolidated financial statements for the three and six months ended June 30, 2016 and 2015: Consolidated Balance Sheet: Consolidated Statement of Operations: Accounts receivable, net Rental revenues Total Current Assets Net revenues Deferred income taxes Gross profit Total Assets Operating income Retained deficit Income before income taxes Total Stockholders’ Equity Income tax (expense) benefit Total Liabilities and Stockholders’ Equity Net income Net income per basic and diluted share The following tables present the effect of the correction discussed above and other adjustments on selected line items of our previously reported consolidated statement of operations for the three and six months ended June 30, 2016 and 2015, respectively. Three months ended June 30, 2016 June 30, 2015 Statement of Operations: As Adjust As As Adjust As Net revenues: Rentals $ 17,185 $ (943 ) $ 16,242 $ 15,616 $ (234 ) $ 15,382 Net revenues 19,066 (943 ) 18,123 17,170 (234 ) 16,936 Gross profit 12,086 (943 ) 11,143 11,854 (234 ) 11,620 Operating income 1,381 (943 ) 438 1,317 (234 ) 1,083 Income (loss) before income taxes 1,061 (943 ) 118 930 (234 ) 696 Income tax (expense) benefit (337 ) 372 35 (147 ) 93 (54 ) Net income (loss) 724 (571 ) 153 783 (141 ) 642 Net income (loss) per share: Basic $ 0.03 $ (0.02 ) $ 0.01 $ 0.03 $ — $ 0.03 Diluted $ 0.03 $ (0.02 ) $ 0.01 $ 0.03 $ — $ 0.03 Six months ended June 30, 2016 June 30, 2015 Statement of Operations: As Adjust As As Adjust As Net revenues: Rentals $ 34,423 $ (1,693 ) $ 32,730 $ 30,755 $ (407 ) $ 30,348 Net revenues 38,110 (1,693 ) 36,417 33,895 (407 ) 33,488 Gross profit 25,393 (1,693 ) 23,700 23,943 (407 ) 23,536 Operating income 2,545 (1,693 ) 852 2,869 (407 ) 2,462 Income (loss) before income taxes 1,940 (1,693 ) 247 230 (407 ) (177 ) Income tax (expense) benefit (721 ) 668 (53 ) 138 161 299 Net income (loss) 1,219 (1,025 ) 194 368 (246 ) 122 Net income (loss) per share: Basic $ 0.05 $ (0.04 ) $ 0.01 $ 0.02 $ (0.01 ) $ 0.01 Diluted $ 0.05 $ (0.04 ) $ 0.01 $ 0.02 $ (0.01 ) $ 0.01 The following tables present the effect of the correction discussed above and other adjustments on selected line items of our previously reported consolidated balance sheet at June 30, 2016 and 2015, respectively. June 30, 2016 June 30, 2015 Balance Sheet: As Adjust As As Adjust As Accounts receivable, net $ 16,953 $ (3,278 ) $ 13,675 $ 12,304 $ (407 ) $ 11,897 Total Current Assets 23,804 (3,278 ) 20,526 18,289 (407 ) 17,882 Deferred income taxes 10,821 1,295 12,116 13,878 161 14,039 Total Assets 100,267 (1,983 ) 98,284 91,779 (246 ) 91,533 Retained deficit (38,743 ) (1,983 ) (40,726 ) (43,336 ) (246 ) (43,582 ) Total Stockholders’ Equity 52,940 (1,983 ) 50,957 47,508 (246 ) 47,262 Total Liabilities and Stockholders’ Equity $ 100,267 $ (1,983 ) $ 98,284 $ 91,779 $ (246 ) $ 91,533

Business Combination

Business Combination	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Business Combination	3. Business Combination On April 20, 2015 (the “Closing Date”), the Company acquired substantially all of the assets of Ciscura Holding Company, Inc. and its subsidiaries (“Ciscura”) for $6.2 million in cash, based on the final number of pumps acquired and the associated treatments, which were generated during the 90-day period post-closing from the approximately 100 medical facility relationships Ciscura had prior to the acquisition. The Company acquired approximately 1,800 infusion pumps, its four-person field sales team, as well as its facilities management personnel, which have become the foundation of the Company’s new Southeast facility. Ciscura, based in Alpharetta, GA, was a privately-held Southeastern regional provider of ambulatory infusion pumps and services to medical facilities and provides the Company with a new regional warehouse and service facility that are in close proximity to a number of our largest existing customers, in addition to new customers previously serviced by Ciscura, enabling same day service for equipment and supplies to much of the Southeast region. The Company used available borrowings under its Credit Facility to finance the acquisition and associated expenses. Final Purchase Price Allocation Pursuant to Accounting Standards Codification (“ASC”) 805, Business Combinations , Amount Medical equipment in rental service $ 2,289 Trade names and Trademarks 23 Customer relationships 3,393 Furniture and fixtures 20 Leasehold improvements 185 Non-competition agreements 246 Total - final purchase price $ 6,156 Acquired property and equipment are being depreciated on a straight-line basis with estimated remaining lives ranging from 1 year to 7 years. Unaudited Pro Forma Financial Information The unaudited pro forma financial information in the table below summarizes the combined results of operations of the Company and Ciscura as though the companies had been combined as of the beginning of the three and six month periods ended June 30, 2015. The pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of the period presented nor is it indicative of future results. The Company did not disclose the revenue and income of Ciscura separately as it is not practical due to the fact that the operations are substantially integrated. The following pro forma financial information presented also includes the pro forma depreciation and amortization charges from acquired tangible and intangible assets, and related tax effects for the three and six months ended June 30, 2015 (in thousands): Three months ended Six months ended June 30, 2015 June 30, 2015 (Restated) (Restated) Revenue $ 17,332 $ 34,750 Net income $ 688 $ 258

Medical Equipment and Property

Medical Equipment and Property	6 Months Ended
	Jun. 30, 2016
Text Block [Abstract]
Medical Equipment and Property	4. Medical Equipment and Property Medical equipment consisted of the following as of June 30, 2016 and December 31, 2015 (in thousands): June 30, December 31, 2016 2015 Medical Equipment held for sale or rental $ 1,524 $ 2,277 Medical Equipment in rental service 58,268 53,681 Medical Equipment in rental service - pump reserve (394 ) (232 ) Accumulated depreciation (28,069 ) (25,612 ) Medical Equipment in rental service - net 29,805 27,837 Total $ 31,329 $ 30,114 Depreciation expense for medical equipment for the three and six months ended June 30, 2016 was $1.6 million and $3.1 million, respectively, compared to $1.1 million and $2.1 million for the same prior year periods, which was recorded in cost of revenues – pump depreciation and disposals, for each period. Depreciation expense for property and equipment for the three and six months ended June 30, 2016 was $0.1 million and $0.3 million, respectively, compared to $0.1 million and $0.2 million for the same prior year periods. This expense was recorded in general and administrative expenses.

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	5. Intangible Assets The carrying amount and accumulated amortization of intangible assets as of June 30, 2016 and December 31, 2015, are as follows (in thousands): June 30, 2016 Gross Accumulated Net Nonamortizable intangible assets Trade names $ 2,000 $ — $ 2,000 Amortizable intangible assets Trade names 23 23 — Physician and customer relationships 32,865 18,041 14,824 Physician and customer relationships - Ciscura 3,393 198 3,195 Non-competition agreements 1,094 992 102 Software 12,663 929 11,734 Total nonamortizable and amortizable intangible assets $ 52,038 $ 20,183 $ 31,855 December 31, 2015 Gross Accumulated Net Nonamortizable intangible assets Trade names $ 2,000 $ — $ 2,000 Amortizable intangible assets Trade names 23 15 8 Physician and customer relationships 32,865 16,946 15,919 Physician and customer relationships - Ciscura 3,393 103 3,290 Non-competition agreements 1,094 930 164 Software 11,942 1,789 10,153 Total nonamortizable and amortizable intangible assets $ 51,317 $ 19,783 $ 31,534 Amortization expense for the three and six months ended June 30, 2016 was $0.9 million and $1.8 million, respectively, compared to $0.7 million and $1.3 million, respectively, for the three and six months ended June 30, 2015. Expected annual amortization expense for intangible assets recorded as of June 30, 2016, is as follows (in thousands): 7/1-12/31/2016 2017 2018 2019 2020 2021 and Amortization expense $ 3,318 $ 6,383 $ 6,018 $ 4,150 $ 2,590 $ 7,396

Debt

Debt	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Debt	6. Debt On March 23, 2015, the Company and its direct and indirect subsidiaries (the “Borrowers”) entered into a credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as lender (the “Lender”). The Credit Agreement consists of a $27.0 million Term Loan A, up to an $8.0 million Term Loan B and a $10.0 million revolving credit facility (the “Revolver”), all of which mature on March 23, 2020 (collectively, the “Credit Facility”). On March 23, 2015, the Borrowers drew $27.0 million under the Term Loan A to repay and terminate the previously existing credit facility under the credit agreement dated November 30, 2012, as amended, by and among the Company, its direct and indirect subsidiaries, Wells Fargo Bank, National Association, as administrative agent, and certain lenders party thereto (the “WF Facility”). As of June 30, 2016, Term Loan B had a balance of $5.9 million. As of June 30, 2016, interest on the Credit Facility is payable at the Borrower’s choice as a (i) Eurodollar Loan, which bears interest at a per annum rate equal to LIBOR plus a margin ranging from 2.00% to 2.50% or (ii) CBFR Loan, which bears interest at a per annum rate equal to (a) the Lender’s prime rate or (b) LIBOR for a 30-day interest period plus 2.50%, in each case, plus a margin ranging from -0.75% to -0.25%. The actual rate at June 30, 2016 was 2.95% (LIBOR of 0.45% plus 2.50%) on both Term Loan A and B and 3.25% (JPM Chase Prime Rate of 3.5% less 0.25%) on the Revolver. The availability under the Revolver is based upon the Borrowers’ eligible accounts receivable and eligible inventory and is comprised as follows (in thousands): June 30, December 31, 2016 2015 Revolver: Gross Availability $ 10,000 $ 10,000 Outstanding Draws (6,618 ) — Letter of Credit — (81 ) Landlord Reserves (45 ) (37 ) Availability on Revolver $ 3,337 $ 9,882 To secure repayment of the obligations of the Borrowers, each Borrower has granted to the Lender, for the benefit of various secured parties, a first priority security interest in substantially all of the personal property assets of each of the Borrowers. In addition, the Company has pledged the shares of InfuSystem Holdings USA, Inc. (“Holdings USA”) and Holdings USA has pledged the shares of each of InfuSystem, Inc. and First Biomedical, Inc. and the equity interests of IFC, LLC to the Lender, for the benefit of the secured parties, to further secure the obligations under the Credit Agreement. In addition, the Credit Agreement requires the Borrowers to maintain the following financial covenant obligations: (i) a minimum fixed charge coverage ratio of 1.25:1.00; (ii) a maximum total leverage ratio ranging from 3.00:1.00 to 2.25:1.00 during specified periods; and (iii) a minimum net worth of $37.5 million. The restatement error and the Company’s decision to prepay debt, would have resulted in the Company being non-compliant with its fixed charge coverage ratio covenant as of March 31, 2016, however, as of June 30, 2016, the Company would have been in compliance. As a result of the Company’s restatement of prior consolidated financial statements described herein, the following Events of Default occurred: (i) an Event of Default that results from breach of the Fixed Charge Coverage covenant as of March 31, 2016 as required under Section 6.12(b); and (ii) an Event of Default that results from the unintentional misrepresentations made prior to the date of the First Amendment in connection with the certification as to the accuracy of the financial statements and compliance certificate delivered pursuant to Section 5.01 as they relate solely to the source of the error that has necessitated the restatement discussed herein. In order to cure these violations, the Company entered into the First Amendment to Credit Agreement and Waiver on December 5, 2016. This First Amendment amends the Credit Agreement in the following material respects: (i) a waiver of the Event of Default that results from the failure to timely deliver the unaudited financial statements for the fiscal quarter ended September 30, 2016 as required under Section 5.01(b) and (c); (ii) a waiver of the Event of Default that results from breach of the Fixed Charge Coverage covenant as of March 31, 2016 as required under Section 6.12(b); (iii) a waiver of the Event of Default that results from the unintentional misrepresentations made prior to the date of the First Amendment in connection with the certification as to the accuracy of the financial statements and compliance certificate delivered pursuant to Section 5.01 as they relate solely to the source of the error that has necessitated the restatement discussed herein; (iv) a restructuring of the credit facility that will effectively consolidate Term Loan A and Term Loan B into a single Term Loan resulting in a new total drawn amount of $32 million under the Term Loan with the approximately $5 million excess over the current aggregate drawn amounts under Term Loan A and Term Loan B to be available to reduce the Company’s drawings under the revolving credit line; (v) set the maturity of the new Term Loan described in item (iv) and the revolving credit line to five years from the effective date of the First Amendment; (vi) set the quarterly mandatory principal payment due on the Term Loan to $1.3 million due on the last business day of each fiscal quarter with any remaining unpaid and outstanding amount due at maturity; (vii) amend the deadline for delivery of consolidated financial statements to allow for the delivery of such statements for the quarter ended September 30, 2016 by December 16, 2016; (viii) amend the deadline for delivery of the Company’s annual financial plan and forecast to 30 days after the end of each fiscal year; (ix) amend the Leverage Ratio covenant to provide for the following schedule of maximum permitted ratios: (i) 3.0 to 1.0 at any time on or after the effective date but prior to December 31, 2015, (ii) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2017, (iii) 2.50 to 1.0 at any time on or after March 31, 2017 but prior to March 31, 2018 or (iv) 2.25 to 1.00 at any time on or after March 31, 2018; (x) amend the definition of EBITDA to provide for the exclusion of certain one-time expenses directly related to the financial restatement described herein; (xi) amend Section 8.01(a) to replace references to “Jonathan Foster” with “Christopher Downs”. As a result of the waivers of Events of Default contained within the First Amendment to Credit and Waiver Agreement described herein, as of June 30, 2016, the Company was in compliance with all such covenants. The Company had approximate future maturities of loans and capital leases as of June 30, 2016 as follows (in thousands): 2016 2017 2018 2019 2020 Total Term Loan A (a) $ — $ 3,860 $ 3,860 $ 3,860 $ 9,630 $ 21,210 Term Loan B 454 908 1,136 1,136 2,261 5,895 Unamortized value of the debt issuance costs (b) (17 ) (31 ) (31 ) (31 ) (8 ) (118 ) Revolver — — — — 6,618 6,618 Capital Leases 1,650 2,591 1,393 166 16 5,816 Total $ 2,087 $ 7,328 $ 6,358 $ 5,131 $ 18,517 $ 39,421 (a) The Company has prepaid its Term Loan A principal payments due on September 30, 2016 and December 31, 2016. Each of these payments is $965, representing a total prepayment of $1,930 (b) Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03 (see Note 11) The following is a breakdown of the Company’s current and long-term debt (including capital leases) as of June 30, 2016 and December 31, 2015 (in thousands): June 30, 2016 December 31, 2015 Current Long-Term Long-Term Total Current Long-Term Long-Term Total Term Loans $ 2,838 $ 24,267 $ 27,105 Term Loans $ 1,873 $ 26,651 $ 28,524 Unamortized value of the debt issuance costs (a) $ — $ (118 ) (118 ) Unamortized value of the debt issuance costs (a) $ — $ (134 ) (134 ) Revolver — 6,618 6,618 Revolver — — — Capital Leases 3,101 2,715 5,816 Capital Leases 3,187 3,233 6,420 Total $ 5,939 $ 33,482 $ 39,421 Total $ 5,060 $ 29,750 $ 34,810 (a) Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03 (see Note 11)

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes During the three and six months ended June 30, 2016, the Company recorded income tax benefit of $0.1 million and tax expense of $0.1 million, respectively. During the three and six months ended June 30, 2015, the Company recorded income tax expense of $0.1 million and an income tax benefit of $0.3 million, respectively. During the quarter, the Company recognized a benefit from research and development credits (“R&D Credits”) of $0.3 million pertaining to its development of software that enables third parties to interact, initiate functions or review data on the Company’s system. In computing its income tax provision, the Company estimates its effective tax rate for the full year and applies that rate to income earned through the reporting period. The Company’s effective income tax rate for the six months ended June 30, 2016 was 21.5%.

Commitments, Contingencies and

Commitments, Contingencies and Litigation	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	8. Commitments, Contingencies and Litigation From time to time in the ordinary course of its business, the Company may be involved in legal proceedings, the outcomes of which may not be determinable. The Company has insurance policies covering potential losses where such coverage is cost effective. The Company is not, at this time, involved in any legal proceedings that the Company believes could have a material effect on the Company’s financial condition, results of operations or cash flows.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share	9. Earnings Per Share Basic income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted income per share assumes the issuance of potentially dilutive shares of common stock during the period. The following table reconciles the numerators and denominators of the basic and diluted income per share computations: Three Months Ended Six Months Ended June 30 June 30 (Restated) (Restated) 2016 2015 2016 2015 Numerator: Net income (in thousands) $ 153 $ 642 $ 194 $ 122 Denominator: Weighted average common shares outstanding: Basic 22,620,386 22,381,487 22,584,462 22,345,309 Dilutive effect of non-vested awards 489,484 443,478 485,438 398,639 Diluted 23,109,870 22,824,965 23,069,900 22,743,948 Net income per share: Basic $ 0.01 $ 0.03 $ 0.01 $ 0.01 Diluted $ 0.01 $ 0.03 $ 0.01 $ 0.01 For the three and six months ended June 30, 2016, less than 0.1 million of stock options were not included in the calculation because they would have an anti-dilutive effect, compared to 0.1 million for the same prior year periods.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events The Company has evaluated subsequent events through the date of issuance for the unaudited condensed consolidated financial statements as of June 30, 2016.

Recent Accounting Pronouncement

Recent Accounting Pronouncements and Developments	6 Months Ended
	Jun. 30, 2016
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements and Developments	11. Recent Accounting Pronouncements and Developments In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”), and, in August 2015, the FASB issued ASU No. 2015-15, Interest – Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements - Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (“ASU 2015-15”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-15 then clarified that debt issuance costs related to a line-of-credit arrangement can be presented as an asset on the balance sheet, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. These ASUs are effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. The Company adopted this guidance as of January 1, 2016, and as a result, has recast the December 31, 2015 consolidated balance sheet to conform to the current period presentation. The adoption of this standard reduced previously presented other assets and long-term debt by $0.1 million, based upon the balance of unamortized debt issuance costs relating to its Credit Facility as of December 31, 2015. On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will supersede the existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either a retrospective or cumulative effect transition method. In August 2015, the FASB issued ASU No. 2015-14, deferring the effective date of ASU 2014-09 by one year, from January 1, 2017 to January 1, 2018. The Company plans to adopt ASU 2014-09 on January 1, 2018. The Company is evaluating the effect that ASU 2014-09 will have on its financial position, results of operations, cash flows and/or disclosures and has not yet selected a transition method. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures.

Business Combination (Policies)

Business Combination (Policies)	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Business Combinations	Final Purchase Price Allocation Pursuant to Accounting Standards Codification (“ASC”) 805, Business Combinations , Amount Medical equipment in rental service $ 2,289 Trade names and Trademarks 23 Customer relationships 3,393 Furniture and fixtures 20 Leasehold improvements 185 Non-competition agreements 246 Total - final purchase price $ 6,156 Acquired property and equipment are being depreciated on a straight-line basis with estimated remaining lives ranging from 1 year to 7 years.
Recent Accounting Pronouncements and Developments	In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”), and, in August 2015, the FASB issued ASU No. 2015-15, Interest – Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements - Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (“ASU 2015-15”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-15 then clarified that debt issuance costs related to a line-of-credit arrangement can be presented as an asset on the balance sheet, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. These ASUs are effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. The Company adopted this guidance as of January 1, 2016, and as a result, has recast the December 31, 2015 consolidated balance sheet to conform to the current period presentation. The adoption of this standard reduced previously presented other assets and long-term debt by $0.1 million, based upon the balance of unamortized debt issuance costs relating to its Credit Facility as of December 31, 2015. On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will supersede the existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either a retrospective or cumulative effect transition method. In August 2015, the FASB issued ASU No. 2015-14, deferring the effective date of ASU 2014-09 by one year, from January 1, 2017 to January 1, 2018. The Company plans to adopt ASU 2014-09 on January 1, 2018. The Company is evaluating the effect that ASU 2014-09 will have on its financial position, results of operations, cash flows and/or disclosures and has not yet selected a transition method. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures.

Restatement of Previously Iss18

Restatement of Previously Issued Consolidated Financial Statements (Tables)	6 Months Ended
	Jun. 30, 2016
Accounting Changes and Error Corrections [Abstract]
Schedule of Unaudited Quarterly Impact on Company's Financial Statements	The impact on the Company’s financial statements for the three and six months ended June 30, 2016 and 2015 is to increase the provision for contractual allowance (thereby reducing accounts receivable as shown on the balance sheet): Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) 2016 2015 2016 2015 Unaudited quarterly impact $ 943 $ 234 $ 1,693 $ 407
Schedule of Effect of Correction and Other Adjustments on Previously Reported Consolidated Statements	The following tables present the effect of the correction discussed above and other adjustments on selected line items of our previously reported consolidated statement of operations for the three and six months ended June 30, 2016 and 2015, respectively. Three months ended June 30, 2016 June 30, 2015 Statement of Operations: As Adjust As As Adjust As Net revenues: Rentals $ 17,185 $ (943 ) $ 16,242 $ 15,616 $ (234 ) $ 15,382 Net revenues 19,066 (943 ) 18,123 17,170 (234 ) 16,936 Gross profit 12,086 (943 ) 11,143 11,854 (234 ) 11,620 Operating income 1,381 (943 ) 438 1,317 (234 ) 1,083 Income (loss) before income taxes 1,061 (943 ) 118 930 (234 ) 696 Income tax (expense) benefit (337 ) 372 35 (147 ) 93 (54 ) Net income (loss) 724 (571 ) 153 783 (141 ) 642 Net income (loss) per share: Basic $ 0.03 $ (0.02 ) $ 0.01 $ 0.03 $ — $ 0.03 Diluted $ 0.03 $ (0.02 ) $ 0.01 $ 0.03 $ — $ 0.03 Six months ended June 30, 2016 June 30, 2015 Statement of Operations: As Adjust As As Adjust As Net revenues: Rentals $ 34,423 $ (1,693 ) $ 32,730 $ 30,755 $ (407 ) $ 30,348 Net revenues 38,110 (1,693 ) 36,417 33,895 (407 ) 33,488 Gross profit 25,393 (1,693 ) 23,700 23,943 (407 ) 23,536 Operating income 2,545 (1,693 ) 852 2,869 (407 ) 2,462 Income (loss) before income taxes 1,940 (1,693 ) 247 230 (407 ) (177 ) Income tax (expense) benefit (721 ) 668 (53 ) 138 161 299 Net income (loss) 1,219 (1,025 ) 194 368 (246 ) 122 Net income (loss) per share: Basic $ 0.05 $ (0.04 ) $ 0.01 $ 0.02 $ (0.01 ) $ 0.01 Diluted $ 0.05 $ (0.04 ) $ 0.01 $ 0.02 $ (0.01 ) $ 0.01 The following tables present the effect of the correction discussed above and other adjustments on selected line items of our previously reported consolidated balance sheet at June 30, 2016 and 2015, respectively. June 30, 2016 June 30, 2015 Balance Sheet: As Adjust As As Adjust As Accounts receivable, net $ 16,953 $ (3,278 ) $ 13,675 $ 12,304 $ (407 ) $ 11,897 Total Current Assets 23,804 (3,278 ) 20,526 18,289 (407 ) 17,882 Deferred income taxes 10,821 1,295 12,116 13,878 161 14,039 Total Assets 100,267 (1,983 ) 98,284 91,779 (246 ) 91,533 Retained deficit (38,743 ) (1,983 ) (40,726 ) (43,336 ) (246 ) (43,582 ) Total Stockholders’ Equity 52,940 (1,983 ) 50,957 47,508 (246 ) 47,262 Total Liabilities and Stockholders’ Equity $ 100,267 $ (1,983 ) $ 98,284 $ 91,779 $ (246 ) $ 91,533

Business Combination (Tables)

Business Combination (Tables)	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Summary of Final Purchase Price Allocation	The allocation of the final purchase price to the fair values of the assets acquired and liabilities assumed as of the Closing Date is presented below (in thousands): Amount Medical equipment in rental service $ 2,289 Trade names and Trademarks 23 Customer relationships 3,393 Furniture and fixtures 20 Leasehold improvements 185 Non-competition agreements 246 Total - final purchase price $ 6,156
Summary of Pro Forma Financial Information Includes Depreciation and Amortization Charges	The following pro forma financial information presented also includes the pro forma depreciation and amortization charges from acquired tangible and intangible assets, and related tax effects for the three and six months ended June 30, 2015 (in thousands): Three months ended Six months ended June 30, 2015 June 30, 2015 (Restated) (Restated) Revenue $ 17,332 $ 34,750 Net income $ 688 $ 258

Medical Equipment and Property

Medical Equipment and Property (Tables)	6 Months Ended
	Jun. 30, 2016
Text Block [Abstract]
Summary of Medical Equipment	Medical equipment consisted of the following as of June 30, 2016 and December 31, 2015 (in thousands): June 30, December 31, 2016 2015 Medical Equipment held for sale or rental $ 1,524 $ 2,277 Medical Equipment in rental service 58,268 53,681 Medical Equipment in rental service - pump reserve (394 ) (232 ) Accumulated depreciation (28,069 ) (25,612 ) Medical Equipment in rental service - net 29,805 27,837 Total $ 31,329 $ 30,114

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets	The carrying amount and accumulated amortization of intangible assets as of June 30, 2016 and December 31, 2015, are as follows (in thousands): June 30, 2016 Gross Accumulated Net Nonamortizable intangible assets Trade names $ 2,000 $ — $ 2,000 Amortizable intangible assets Trade names 23 23 — Physician and customer relationships 32,865 18,041 14,824 Physician and customer relationships - Ciscura 3,393 198 3,195 Non-competition agreements 1,094 992 102 Software 12,663 929 11,734 Total nonamortizable and amortizable intangible assets $ 52,038 $ 20,183 $ 31,855 December 31, 2015 Gross Accumulated Net Nonamortizable intangible assets Trade names $ 2,000 $ — $ 2,000 Amortizable intangible assets Trade names 23 15 8 Physician and customer relationships 32,865 16,946 15,919 Physician and customer relationships - Ciscura 3,393 103 3,290 Non-competition agreements 1,094 930 164 Software 11,942 1,789 10,153 Total nonamortizable and amortizable intangible assets $ 51,317 $ 19,783 $ 31,534
Schedule of Expected Annual Amortization Expense for Intangible Assets	Expected annual amortization expense for intangible assets recorded as of June 30, 2016, is as follows (in thousands): 7/1-12/31/2016 2017 2018 2019 2020 2021 and Amortization expense $ 3,318 $ 6,383 $ 6,018 $ 4,150 $ 2,590 $ 7,396

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Summary of Revolver Based upon Borrowers' Eligible Accounts Receivable and Inventory	The availability under the Revolver is based upon the Borrowers’ eligible accounts receivable and eligible inventory and is comprised as follows (in thousands): June 30, December 31, 2016 2015 Revolver: Gross Availability $ 10,000 $ 10,000 Outstanding Draws (6,618 ) — Letter of Credit — (81 ) Landlord Reserves (45 ) (37 ) Availability on Revolver $ 3,337 $ 9,882
Summary of Future Maturities of Loans and Capital Leases	The Company had approximate future maturities of loans and capital leases as of June 30, 2016 as follows (in thousands): 2016 2017 2018 2019 2020 Total Term Loan A (a) $ — $ 3,860 $ 3,860 $ 3,860 $ 9,630 $ 21,210 Term Loan B 454 908 1,136 1,136 2,261 5,895 Unamortized value of the debt issuance costs (b) (17 ) (31 ) (31 ) (31 ) (8 ) (118 ) Revolver — — — — 6,618 6,618 Capital Leases 1,650 2,591 1,393 166 16 5,816 Total $ 2,087 $ 7,328 $ 6,358 $ 5,131 $ 18,517 $ 39,421 (a) The Company has prepaid its Term Loan A principal payments due on September 30, 2016 and December 31, 2016. Each of these payments is $965, representing a total prepayment of $1,930 (b) Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03 (see Note 11)
Summary of Company's Current and Long-Term Debt (Including Capital Leases)	The following is a breakdown of the Company’s current and long-term debt (including capital leases) as of June 30, 2016 and December 31, 2015 (in thousands): June 30, 2016 December 31, 2015 Current Long-Term Long-Term Total Current Long-Term Long-Term Total Term Loans $ 2,838 $ 24,267 $ 27,105 Term Loans $ 1,873 $ 26,651 $ 28,524 Unamortized value of the debt issuance costs (a) $ — $ (118 ) (118 ) Unamortized value of the debt issuance costs (a) $ — $ (134 ) (134 ) Revolver — 6,618 6,618 Revolver — — — Capital Leases 3,101 2,715 5,816 Capital Leases 3,187 3,233 6,420 Total $ 5,939 $ 33,482 $ 39,421 Total $ 5,060 $ 29,750 $ 34,810 (a) Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03 (see Note 11)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Numerators and Denominators of Basic and Diluted Income per Share	The following table reconciles the numerators and denominators of the basic and diluted income per share computations: Three Months Ended Six Months Ended June 30 June 30 (Restated) (Restated) 2016 2015 2016 2015 Numerator: Net income (in thousands) $ 153 $ 642 $ 194 $ 122 Denominator: Weighted average common shares outstanding: Basic 22,620,386 22,381,487 22,584,462 22,345,309 Dilutive effect of non-vested awards 489,484 443,478 485,438 398,639 Diluted 23,109,870 22,824,965 23,069,900 22,743,948 Net income per share: Basic $ 0.01 $ 0.03 $ 0.01 $ 0.01 Diluted $ 0.01 $ 0.03 $ 0.01 $ 0.01

Restatement of Previously Iss24

Restatement of Previously Issued Consolidated Financial Statements - Schedule of Unaudited Quarterly Impact on Company's Financial Statements (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Accounting Changes and Error Corrections [Abstract]
Unaudited quarterly impact	$ 943	$ 234	$ 1,693	$ 407

Restatement of Previously Iss25

Restatement of Previously Issued Consolidated Financial Statements - Schedule of Effect of Correction and Other Adjustments on Previously Reported Consolidated Statement of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Net revenues:
Rentals	$ 16,242	$ 15,382	$ 32,730	$ 30,348
Net revenues	18,123	16,936	36,417	33,488
Gross profit	11,143	11,620	23,700	23,536
Operating income	438	1,083	852	2,462
Income (loss) before income taxes	118	696	247	(177)
Income tax (expense) benefit	35	(54)	(53)	299
Net income (loss)	$ 153	$ 642	$ 194	$ 122
Net income (loss) per share:
Basic	$ 0.01	$ 0.03	$ 0.01	$ 0.01
Diluted	$ 0.01	$ 0.03	$ 0.01	$ 0.01
As Previously Reported [Member]
Net revenues:
Rentals	$ 17,185	$ 15,616	$ 34,423	$ 30,755
Net revenues	19,066	17,170	38,110	33,895
Gross profit	12,086	11,854	25,393	23,943
Operating income	1,381	1,317	2,545	2,869
Income (loss) before income taxes	1,061	930	1,940	230
Income tax (expense) benefit	(337)	(147)	(721)	138
Net income (loss)	$ 724	$ 783	$ 1,219	$ 368
Net income (loss) per share:
Basic	$ 0.03	$ 0.03	$ 0.05	$ 0.02
Diluted	$ 0.03	$ 0.03	$ 0.05	$ 0.02
Adjustment [Member]
Net revenues:
Rentals	$ (943)	$ (234)	$ (1,693)	$ (407)
Net revenues	(943)	(234)	(1,693)	(407)
Gross profit	(943)	(234)	(1,693)	(407)
Operating income	(943)	(234)	(1,693)	(407)
Income (loss) before income taxes	(943)	(234)	(1,693)	(407)
Income tax (expense) benefit	372	93	668	161
Net income (loss)	$ (571)	$ (141)	$ (1,025)	$ (246)
Net income (loss) per share:
Basic	$ (0.02)		$ (0.04)	$ (0.01)
Diluted	$ (0.02)		$ (0.04)	$ (0.01)

Corrections to Previously Issue

Corrections to Previously Issued Consolidated Financial Statements - Schedule of Effect of Correction and Other Adjustments on Previously Reported Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable, net	$ 13,675	$ 12,622	$ 11,897
Total Current Assets	20,526	18,960	17,882
Deferred income taxes	12,116	12,128	14,039
Total Assets	98,284	95,357	91,533
Retained deficit	(40,726)	(40,920)	(43,582)
Total Stockholders' Equity	50,957	50,320	47,262
Total Liabilities and Stockholders' Equity	98,284	$ 95,357	91,533
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable, net	16,953		12,304
Total Current Assets	23,804		18,289
Deferred income taxes	10,821		13,878
Total Assets	100,267		91,779
Retained deficit	(38,743)		(43,336)
Total Stockholders' Equity	52,940		47,508
Total Liabilities and Stockholders' Equity	100,267		91,779
Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable, net	(3,278)		(407)
Total Current Assets	(3,278)		(407)
Deferred income taxes	1,295		161
Total Assets	(1,983)		(246)
Retained deficit	(1,983)		(246)
Total Stockholders' Equity	(1,983)		(246)
Total Liabilities and Stockholders' Equity	$ (1,983)		$ (246)

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - Ciscura [Member] $ in Millions	Apr. 20, 2015USD ($)Medical_FacilityInfusionPump	Jun. 30, 2016
Business Acquisition [Line Items]
Purchase price | $	$ 6.2
Number of medical facility relationships prior to acquisition | Medical_Facility	100
Number of infusion pumps acquired | InfusionPump	1,800
Minimum [Member]
Business Acquisition [Line Items]
Property and equipment, estimated remaining lives		1 year
Maximum [Member]
Business Acquisition [Line Items]
Property and equipment, estimated remaining lives		7 years

Business Combinations - Summary

Business Combinations - Summary of Final Purchase Price Allocation (Detail) - Ciscura [Member] $ in Thousands	Apr. 20, 2015USD ($)
Business Acquisition [Line Items]
Medical equipment in rental service	$ 2,289
Total - final purchase price	6,156
Furniture, Fixtures, and Equipment [Member]
Business Acquisition [Line Items]
Property, plant, and equipment	20
Leasehold Improvements [Member]
Business Acquisition [Line Items]
Property, plant, and equipment	185
Trademarks and Trade Names [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets	23
Customer Relationships [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets	3,393
Non-Compete Agreements [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets	$ 246

Business Combinations - Summa29

Business Combinations - Summary of Pro Forma Financial Information Includes Depreciation and Amortization Charges (Detail) - Ciscura [Member] - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2015
Business Acquisition [Line Items]
Revenue	$ 17,332	$ 34,750
Net income	$ 688	$ 258

Medical Equipment and Propert30

Medical Equipment and Property - Summary of Medical Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Medical Equipment And Property [Abstract]
Medical equipment held for sale or rental	$ 1,524	$ 2,277
Medical Equipment in rental service	58,268	53,681
Medical Equipment in rental service - pump reserve	(394)	(232)
Accumulated depreciation	(28,069)	(25,612)
Medical Equipment in rental service - net	29,805	27,837
Total	$ 31,329	$ 30,114

Medical Equipment and Propert31

Medical Equipment and Property - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense for medical equipment	$ 1.6	$ 1.1	$ 3.1	$ 2.1
Total depreciation expense recorded	$ 0.1	$ 0.1	$ 0.3	$ 0.2

Intangible Assets - Summary of

Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Total nonamortizable and amortizable intangible assets, Gross Assets	$ 52,038	$ 51,317
Total nonamortizable and amortizable intangible assets, Accumulated Amortization	20,183	19,783
Total nonamortizable and amortizable intangible assets, Net	31,855	31,534
Trade Names [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	23	23
Amortizable intangible assets, Accumulated Amortization	23	15
Amortizable intangible assets, Net		8
Physician and Customer Relationships [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	32,865	32,865
Amortizable intangible assets, Accumulated Amortization	18,041	16,946
Amortizable intangible assets, Net	14,824	15,919
Non-Compete Agreements [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	1,094	1,094
Amortizable intangible assets, Accumulated Amortization	992	930
Amortizable intangible assets, Net	102	164
Software [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	12,663	11,942
Amortizable intangible assets, Accumulated Amortization	929	1,789
Amortizable intangible assets, Net	11,734	10,153
Ciscura [Member] | Physician and Customer Relationships [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	3,393	3,393
Amortizable intangible assets, Accumulated Amortization	198	103
Amortizable intangible assets, Net	3,195	3,290
Trade Names [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Nonamortizable intangible assets	$ 2,000	$ 2,000

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 922	$ 713	$ 1,834	$ 1,344

Intangible Assets - Schedule of

Intangible Assets - Schedule of Expected Annual Amortization Expense for Intangible Assets (Detail) $ in Thousands	Jun. 30, 2016USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense, 2016	$ 3,318
Amortization expense, 2017	6,383
Amortization expense, 2018	6,018
Amortization expense, 2019	4,150
Amortization expense, 2020	2,590
Amortization expense, 2021 and thereafter	$ 7,396

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Dec. 05, 2016	Jun. 30, 2016	Dec. 31, 2015	Mar. 23, 2015
Line of Credit Facility [Line Items]
Deadline of annual financial plan and forecast period		30 days
Amendment to Credit Agreement, description		Amend the Leverage Ratio covenant to provide for the following schedule of maximum permitted ratios: (i) 3.0 to 1.0 at any time on or after the effective date but prior to December 31, 2015, (ii) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2017, (iii) 2.50 to 1.0 at any time on or after March 31, 2017 but prior to March 31, 2018 or (iv) 2.25 to 1.00 at any time on or after March 31, 2018.
JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Credit facility, maturity date		Mar. 23, 2020
Term Loan A [Member]
Line of Credit Facility [Line Items]
Current borrowings under credit facility				$ 27,000,000
Term Loan A [Member] | JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Line of credit facility				27,000,000
Term Loan B [Member]
Line of Credit Facility [Line Items]
Remaining available balance		$ 5,900,000
Term Loan B [Member] | JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Line of credit facility				8,000,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Current borrowings under credit facility		6,618,000
Remaining available balance		$ 3,337,000	$ 9,882,000
Revolving Credit Facility [Member] | JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Line of credit facility				$ 10,000,000
Credit Facility [Member]
Line of Credit Facility [Line Items]
Minimum fixed charge coverage ratio		125.00%
Minimum net worth		$ 37,500,000
CBFR Loans [Member]
Line of Credit Facility [Line Items]
Interest on the credit facility, description		CBFR Loan, which bears interest at a per annum rate equal to (a) the Lender's prime rate or (b) LIBOR for a 30-day interest period plus 2.50%, in each case, plus a margin ranging from -0.75% to -0.25%.
Term Loan [Member]
Line of Credit Facility [Line Items]
Credit facility, maturity period		5 years
Frequency of period payment		Set the quarterly mandatory principal payment due on the Term Loan to $1.3 million due on the last business day of each fiscal quarter with any remaining unpaid and outstanding amount due at maturity.
LIBOR [Member] | Term Loan A [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate		2.50%
Effective fixed interest rate		2.95%
Debt instrument floor rate		0.45%
LIBOR [Member] | Term Loan B [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate		2.50%
Effective fixed interest rate		2.95%
Debt instrument floor rate		0.45%
LIBOR [Member] | CBFR Loans [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate		2.50%
JPM Chase Prime Rate [Member] | Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate		0.25%
Effective fixed interest rate		3.25%
Debt instrument floor rate		3.50%
Eurodollar [Member]
Line of Credit Facility [Line Items]
Interest on the credit facility, description		Eurodollar Loan, which bears interest at a per annum rate equal to LIBOR plus a margin ranging from 2.00% to 2.50%
Subsequent Event [Member] | Term Loan [Member] | First Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Current borrowings under credit facility	$ 32,000,000
Additional available balance	5,000,000
Debt instrument period payment, principal amount	$ 1,300,000
Minimum [Member] | Credit Facility [Member]
Line of Credit Facility [Line Items]
Leverage ratio for remainder period		225.00%
Minimum [Member] | LIBOR [Member] | CBFR Loans [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate		(0.25%)
Minimum [Member] | Eurodollar LIBOR Rate [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate		2.00%
Maximum [Member] | Credit Facility [Member]
Line of Credit Facility [Line Items]
Leverage ratio for remainder period		300.00%
Maximum [Member] | LIBOR [Member] | CBFR Loans [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate		(0.75%)
Maximum [Member] | Eurodollar LIBOR Rate [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate		2.50%
Maximum [Member] | Subsequent Event [Member] | First Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
After amendment, maximum leverage covenant ratio at any time on or after the effective date but prior to December 31, 2015	300.00%
After amendment, maximum leverage covenant ratio at any time on or after December 31, 2015 but prior to March 31, 2017	275.00%
After amendment, maximum leverage covenant ratio at any time on or after March 31, 2017 but prior to March 31, 2018	250.00%
After amendment, maximum leverage covenant ratio at any time on or after March 31, 2018	225.00%

Debt - Summary of Revolver Base

Debt - Summary of Revolver Based upon Borrowers' Eligible Accounts Receivable and Inventory (Detail) - Revolving Credit Facility [Member] - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Line of Credit Facility [Line Items]
Gross Availability	$ 10,000	$ 10,000
Outstanding Draws	(6,618)
Letter of Credit		(81)
Landlord Reserves	(45)	(37)
Availability on Revolver	$ 3,337	$ 9,882

Debt - Summary of Future Maturi

Debt - Summary of Future Maturities of Loans and Capital Leases (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Line of Credit Facility [Line Items]
2,016	$ 2,087
2,017	7,328
2,018	6,358
2,019	5,131
2,020	18,517
Total	39,421	$ 34,810
Unamortized value of the debt issuance costs, 2016	(17)
Unamortized value of the debt issuance costs, 2017	(31)
Unamortized value of the debt issuance costs, 2018	(31)
Unamortized value of the debt issuance costs, 2019	(31)
Unamortized value of the debt issuance costs, 2020	(8)
Unamortized value of the debt issuance costs, Total	(118)	(134)
Term Loan A [Member]
Line of Credit Facility [Line Items]
2,017	3,860
2,018	3,860
2,019	3,860
2,020	9,630
Total	21,210
Term Loan B [Member]
Line of Credit Facility [Line Items]
2,016	454
2,017	908
2,018	1,136
2,019	1,136
2,020	2,261
Total	5,895
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
2,020	6,618
Total	6,618
Capital Leases [Member]
Line of Credit Facility [Line Items]
2,016	1,650
2,017	2,591
2,018	1,393
2,019	166
2,020	16
Total	$ 5,816	$ 6,420

Debt - Summary of Future Matu38

Debt - Summary of Future Maturities of Loans and Capital Leases (Parenthetical) (Detail) - Term Loan A [Member] $ in Thousands	Jun. 30, 2016USD ($)
Line of Credit Facility [Line Items]
Prepaid principal payment amount	$ 1,930
September 30, 2016 [Member]
Line of Credit Facility [Line Items]
Prepaid principal payment amount	965
December 31, 2016 [Member]
Line of Credit Facility [Line Items]
Prepaid principal payment amount	$ 965

Debt - Summary of Company's Cur

Debt - Summary of Company's Current and Long-Term Debt (Including Capital Leases) (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Line of Credit Facility [Line Items]
Current portion of long-term debt	$ 5,939	$ 5,060
Long-Term Debt	33,482	29,750
Total	39,421	34,810
Unamortized value of the debt issuance costs, Current Portion of Long-Term Debt	0	0
Unamortized value of the debt issuance costs, Long-Term Debt	(118)	(134)
Unamortized value of the debt issuance costs, Total	(118)	(134)
Term Loans [Member]
Line of Credit Facility [Line Items]
Current portion of long-term debt	2,838	1,873
Long-Term Debt	24,267	26,651
Total	27,105	28,524
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Long-Term Debt	6,618
Total	6,618
Capital Leases [Member]
Line of Credit Facility [Line Items]
Current portion of long-term debt	3,101	3,187
Long-Term Debt	2,715	3,233
Total	$ 5,816	$ 6,420

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ (35)	$ 54	$ 53	$ (299)
Research and development credits	$ 300
Effective income tax rate			21.50%

Earnings Per Share - Numerators

Earnings Per Share - Numerators and Denominators of Basic and Diluted Income per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Numerator:
Net income (loss)	$ 153	$ 642	$ 194	$ 122
Weighted average common shares outstanding:
Basic	22,620,386	22,381,487	22,584,462	22,345,309
Dilutive effect of non-vested awards	489,484	443,478	485,438	398,639
Diluted	23,109,870	22,824,965	23,069,900	22,743,948
Net income (loss) per share:
Basic	$ 0.01	$ 0.03	$ 0.01	$ 0.01
Diluted	$ 0.01	$ 0.03	$ 0.01	$ 0.01

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - Stock Options [Member] - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Summary Of Significant Accounting Policies [Line Items]
Shares with anti-dilutive effect		100,000		100,000
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Shares with anti-dilutive effect	100,000		100,000

Recent Accounting Pronounceme43

Recent Accounting Pronouncements and Developments - Additional Information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2016USD ($)
Accounting Changes and Error Corrections [Abstract]
Reduction in other assets	$ 0.1
Reduction in long-term debt	$ 0.1